Recombinant PDCD1 (Cemiplimab Biosimilar) anticorps

N° du produit ABIN7795092

L’anticorps anti-PDCD1 (Cemiplimab Biosimilar) Monoclonal Souris est utilisé pour la détection de PDCD1 (Cemiplimab Biosimilar) dans des échantillons de Humain. Il a été validé pour FACS et in vivo.

Aperçu rapide pour Recombinant PDCD1 (Cemiplimab Biosimilar) anticorps (ABIN7795092)

Antigène: PDCD1 (Cemiplimab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp PDCD1 (Cemiplimab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-PDCD1 (Cemiplimab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Cemiplimab Biosimilar, PD-1 Monoclonal Antibody

Attributs du produit: Cemiplimab Biosimilar uses the same protein sequences as the therapeutic antibody cemiplimab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1). Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. Binding of the programmed death receptor (PD) ligands PD-L1 and PD-L2, to the PD-1 receptor inhibits T-cell proliferation and cytokine production. The upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway may contribute to the inhibition of active T-cell immune surveillance of tumors. Cemiplimab is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands, causing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In mouse tumor models, blocking PD-1 activity resulted in decreased rates of tumor growth.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human PD1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur PDCD1 (Cemiplimab Biosimilar)

Antigène: PDCD1 (Cemiplimab Biosimilar)

Autre désignation: Cemiplimab Biosimilar

Classe de substances: Biosimilar